← Leaderboards
Ravi Radhakrishnan
Yale University
$6,158,626
Attributed
$14,891,079
Total exposure
13
Grants
10
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.1M · FY2006–25$2.5M$1.9M$1.3M$625K$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$14,891,079 · 13
By mechanism
U01$9,922,020 · 3
R01$3,418,163 · 1
U54$1,545,385 · 1
P41$5,511 · 8
Top collaborators
- Wei Guo11 shared
- Valerie Marie Weaver11 shared
- Arjun Raj7 shared
- Ashani T Weeraratna7 shared
- David M Eckmann5 shared
- William S. Hlavacek5 shared
- Boris N Kholodenko5 shared
- Mark A. Lemmon5 shared
Most similar at Yale University
Same institution · by research overlap
- Mark A. Lemmon$27,011,161
- Boris N Kholodenko$3,772,867
- Gil G Mor$13,879,233
- Tarek Fahmy$1,970,187
- Jan K Czyzyk$501,117
Others in their field
Top investigators on “Molecular”
- David Heimbrook · Leidos Biomedical Research, Inc.$871,088,761
- Leonard Freedman · Leidos Biomedical Research, Inc.$468,573,385
- Richard Webby · St. Jude Children'S Research Hospital$254,843,170
- Larry Arthur$238,531,074
- Gregory H Reaman · National Childhood Cancer Foundation$230,630,913
- Ralph Parchment · Leidos Biomedical Research, Inc.$193,231,914
Research focus
MolecularCellsPathway InteractionsIn VivoSignal TransductionResistanceExperimental StudyBaseMalignant NeoplasmsTumorMediatingIn VitroAffectLinkResponseNeoplastic CellResearch PersonnelMulti-Scale ModelingPreventMechanicsCellular BiologySpecificityTraffickingGenetically Engineered Mouse
Grant awards (41)
A physical sciences approach to investigate the role of exosomes in metastatic progression$672,673
U01 · FY2025 · CA · contact PI
Multiscale Modeling to Optimize Inhibition of Oncogenic ERK Pathway Signaling$643,676
R01 · FY2024 · CA
A physical sciences approach to investigate the role of exosomes in metastatic progression$639,040
U01 · FY2024 · CA · contact PI
A physical sciences approach to investigate the role of exosomes in metastatic progression$111,985
U01 · FY2024 · CA · contact PI
A physical sciences approach to investigate the role of exosomes in metastatic progression$77,375
U01 · FY2024 · CA · contact PI
Multiscale Modeling to Optimize Inhibition of Oncogenic ERK Pathway Signaling$669,574
R01 · FY2023 · CA
A physical sciences approach to investigate the role of exosomes in metastatic progression$659,220
U01 · FY2023 · CA · contact PI
A physical sciences approach to investigate the role of exosomes in metastatic progression$115,522
U01 · FY2023 · CA · contact PI
A physical sciences approach to investigate the role of exosomes in metastatic progression$80,309
U01 · FY2023 · CA · contact PI
Multiscale Modeling to Optimize Inhibition of Oncogenic ERK Pathway Signaling$674,422
R01 · FY2022 · CA
A physical sciences approach to investigate the role of exosomes in metastatic progression$659,220
U01 · FY2022 · CA · contact PI
A plasticity and reprogramming paradigm for therapy resistance at the single cell level$555,518
U01 · FY2022 · CA
A physical sciences approach to investigate the role of exosomes in metastatic progression$117,879
U01 · FY2022 · CA · contact PI
A physical sciences approach to investigate the role of exosomes in metastatic progression$82,448
U01 · FY2022 · CA · contact PI
Multiscale Modeling to Optimize Inhibition of Oncogenic ERK Pathway Signaling$693,342
R01 · FY2021 · CA
A physical sciences approach to investigate the role of exosomes in metastatic progression$688,299
U01 · FY2021 · CA · contact PI
A plasticity and reprogramming paradigm for therapy resistance at the single cell level$556,945
U01 · FY2021 · CA
A plasticity and reprogramming paradigm for therapy resistance at the single cell level$39,983
U01 · FY2021 · CA
A plasticity and reprogramming paradigm for therapy resistance at the single cell level$809,629
U01 · FY2020 · CA
Multiscale Modeling to Optimize Inhibition of Oncogenic ERK Pathway Signaling$737,149
R01 · FY2020 · CA
A plasticity and reprogramming paradigm for therapy resistance at the single cell level$642,885
U01 · FY2019 · CA
Project 2: Physical Mechanisms and Clinical Implications of Mechano-transduction$287,594
U54 · FY2019 · CA · contact PI
A plasticity and reprogramming paradigm for therapy resistance at the single cell level$139,492
U01 · FY2019 · CA
A plasticity and reprogramming paradigm for therapy resistance at the single cell level$598,501
U01 · FY2018 · CA
Project 2: Physical Mechanisms and Clinical Implications of Mechano-transduction$305,963
U54 · FY2018 · CA · contact PI
Bridging multiple scales in modeling targeted drug nanocarrier delivery$540,424
U01 · FY2017 · EB
Project 2: Physical Mechanisms and Clinical Implications of Mechano-transduction$321,413
U54 · FY2017 · CA · contact PI
Bridging multiple scales in modeling targeted drug nanocarrier delivery$540,424
U01 · FY2016 · EB
Project 2: Physical Mechanisms and Clinical Implications of Mechano-transduction$326,372
U54 · FY2016 · CA · contact PI
Bridging multiple scales in modeling targeted drug nanocarrier delivery$529,615
U01 · FY2015 · EB
Project 2: Physical Mechanisms and Clinical Implications of Mechano-transduction$304,043
U54 · FY2015 · CA · contact PI
Bridging multiple scales in modeling targeted drug nanocarrier delivery$524,210
U01 · FY2014 · EB
Bridging multiple scales in modeling targeted drug nanocarrier delivery$540,424
U01 · FY2013 · EB
THEORETICAL INVESTIGATIONS OF DNA POLYMERASES$1,094
P41 · FY2011 · RR · contact PI
THEORETICAL INVESTIGATIONS OF DNA POLYMERASES$1,091
P41 · FY2010 · RR · contact PI
THEORETICAL INVESTIGATIONS OF DNA POLYMERASES$771
P41 · FY2009 · RR · contact PI
COMPOUNDS FOR SELECTIVE KINASE INHIBITION$473
P41 · FY2008 · RR · contact PI
THEORETICAL INVESTIGATIONS OF DNA POLYMERASES$473
P41 · FY2008 · RR · contact PI
COMPOUNDS FOR SELECTIVE KINASE INHIBITION$299
P41 · FY2007 · RR · contact PI
THEORETICAL INVESTIGATIONS OF DNA POLYMERASES$298
P41 · FY2007 · RR · contact PI
THEORETICAL INVESTIGATIONS OF DNA POLYMERASES$1,012
P41 · FY2006 · RR · contact PI